Tim-3: Biomarqueur et cible thérapeutique en cancérologie

Clémence Granier, Alain Gey, Charles Dariane, Arnaud Mejean, Marc Olivier Timsit, Charlotte Blanc, Virginie Verkarre, Camélia Radulescu, Elisabeth Fabre, Yann Vano, Stéphane Oudard, Cécile Badoual, Éric Tartour

Résultats de recherche: Contribution à un journalArticleRevue par des pairs

6 Citations (Scopus)

Résumé

T cells harboring multiple co-inhibitory molecules lose their anti-tumoral functionality. PD-1 is a clinically approved target in cancer therapy, but its expression alone does not mean dysfunctionality. The expression of Tim-3 on numerous cell types (T cell, Treg, dendritic cell, myeloid cells) favors tumor escape to immune cells. Within many tumors, PD-1/Tim-3 coexpressing CD8-T cells lose their ability to secrete cytokines (IFNγ, IL-2, TNFα) and their intratumoral infiltration correlates with a bad prognosis. Tim-3 recently appeared as a potential biomarker of anti-PD-1 resistance. Combined blockade of PD-1 and Tim-3 axis demonstrated potent clinical efficacy in preclinical models and reinforced the rationale of using an anti-Tim-3 to override tumor resistance.

Titre traduit de la contributionTim-3: A novel biomarker and therapeutic target in oncology
langue originaleFrançais
Pages (de - à)231-237
Nombre de pages7
journalMedecine/Sciences
Volume34
Numéro de publication3
Les DOIs
étatPublié - 1 mars 2018
Modification externeOui

Contient cette citation